Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b-Reference-Cited by-同舟云学术

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b

Published:2012-08 Issue:4 Volume:54 Page:352-354
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Suzuki Fumitaka,Sezaki Hitomi,Akuta Norio,Suzuki Yoshiyuki,Seko Yuya,Kawamura Yusuke,Hosaka Tetsuya,Kobayashi Masahiro,Saito Satoshi,Arase Yasuji,Ikeda Kenji,Kobayashi Mariko,Mineta Rie,Watahiki Sachiyo,Miyakawa Yuzo,Kumada Hiromitsu

Publisher

Elsevier BV

Subject

Infectious Diseases,Virology

Reference23 articles.

1. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August 2011.

2. Natural history of chronic hepatitis C;Seeff;Hepatology,2002

3. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection;Hezode;N Engl J Med,2009

4. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan;Kumada;J Hepatol,2012

5. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection;McHutchison;N Engl J Med,2009

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characterization of the nonstructural 5A (NS5A) region of hepatitis C virus in Thai blood donors;Archives of Microbiology;2024-04-15

2. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis;Revista do Instituto de Medicina Tropical de São Paulo;2022

3. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents;Clinical Gastroenterology and Hepatology;2021-09

4. Primary HCV Drug Resistance Mutations in Patients with Newly Diagnosed HIV Infection;Problems of Particularly Dangerous Infections;2020-10-22

5. Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases;Biomedicines;2020-04-03